The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. has submitted Form 8.3 to disclose its position in Avadel Pharmaceuticals plc. The filing, dated December 29, 2025, reveals that Vanguard holds an interest in 5,864,238 US$0.01 ordinary shares of Avadel, representing 6.02% of the securities. This position is under the purview of the Irish Takeover Panel Act, 1997 and Takeover Rules, 2022.

Details in the disclosure indicate a recent transaction involving purchases and sales of ordinary shares. Vanguard purchased 584 shares and sold 1,632 shares, both at a price of USD 21.55 per share. The document further mentions that there are no dealings related to cash-settled or stock-settled derivative transactions, nor any related agreements, arrangements, or understandings.

Vanguard's disclosure fulfills obligations under rule 8.3, which requires stakeholders with interests of 1% or more to report their positions.